A Fox News opinion piece reports that the US Food and Drug Administration has launched a new "PreCheck" programme aimed at speeding up domestic drug manufacturing, framed as a move to boost American jobs and shore up the country's medicine supply. The article argues this addresses a long-standing vulnerability: despite decades of warnings from policymakers about reliance on foreign supply chains for essential medicines, more than 70% of the primary manufacturing facilities supplying prescriptions filled in the US remain located overseas.

The piece attributes this offshoring largely to a dense web of state and federal regulations, which meant firms investing millions or billions of dollars to build US manufacturing facilities could see those projects sit idle for up to 14 months awaiting standard post-construction reviews. The author contends this regulatory paralysis has pushed pharmaceutical supply chains further offshore over time, and presents the FDA's PreCheck initiative as a corrective measure intended to cut these delays and encourage manufacturers to build in the United States.